36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Post the sale, Patel family has become the single largest promoter shareholder in the company
The product is backed by required scientific proof and comparative bioequivalence studies
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
The Halol facility was placed under Import Alert by USFDA.
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
The company will submit an action plan on the observations and will engage with US FDA for next steps.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Subscribe To Our Newsletter & Stay Updated
